Canadian Medical Assessment of JINARC Outcomes Registry

  • End date
    Mar 27, 2022
  • participants needed
  • sponsor
    Otsuka Canada Pharmaceutical Inc.
Updated on 27 January 2021


This study is part of the Health Canada approval requirement for tolvaptan and is an observational, non-interventional study (NIS) describing the impact of tolvaptan on ADPKD-related burden of illness as measured with a set of Patient Reported Outcome (PRO) Questionnaires. The study is also describing the time to renal replacement therapy (RRT), such as dialysis and transplantation, and the long-term mortality rate and causes (i.e. renal and hepatic), in ADPKD patients treated with tolvatan (JINARC)

Condition Polycystic Kidney, Autosomal Dominant, autosomal dominant polycystic kidney disease
Clinical Study IdentifierNCT02925221
SponsorOtsuka Canada Pharmaceutical Inc.
Last Modified on27 January 2021


Yes No Not Sure

Inclusion Criteria

ADPKD patients 18 years old at the time of tolvaptan initiation
The treating physician must have reached the decision to treat the patient with tolvaptan as per the Canadian Product Monograph prior to and independently of soliciting the patient to participate in the study
The patient or legal guardian must have signed an informed consent indicating the understanding of the study and allowing the use of their anonymous data for the purposes of the study

Exclusion Criteria

The patient does not comprehend or refuses to sign the informed consent
The patient has any contraindications to the use of tolvaptan as specified in the Canadian Product Monograph
The patient has any condition which, as per the judgment of the treating physician, prohibits them from participating in the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note